ULTI Ultimovacs

Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation

Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation

Oslo, August 15, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its second quarter 2024 results on Wednesday, August 21, 2024.

The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Wednesday, August 21, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.

The report and presentation will be available on the company website from 07:00 CET the same day.

For further information, please see or contact:

Carlos de Sousa, CEO

Email:

Phone:

Hans Vassgård Eid, CFO

Email:

Phone:



 

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act



EN
15/08/2024

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Tr...

Ultimovacs Announces Patient Recruitment Discontinuation in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer Oslo, September 11, 2024: (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announced that the company has agreed with the investigators conducting the LUNGVAC trial () to discontinue patient recruitment. LUNGVAC is an investigator-initiated, randomized Phase II trial designed to assess the impact of UV1 in combination with the checkpoint inhibitor cemiplimab o...

September 11, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial ...

Ultimovacs Announces Updated Data Analysis on UV1 Phase II NIPU Trial in Mesothelioma at ESMO 2024 Oslo, September 9, 2024: (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces the presentation of updated data analysis from the UV1 Phase II NIPU trial (), at the . The NIPU trial evaluated the addition of UV1 telomerase vaccine to immunotherapy with ipilimumab and nivolumab compared with ipilimumab and nivolumab alone, as a second-line treatment for patients with inoperable malignant pleural mesothelioma. As at ESMO 20...

September 8, 2024 1 EN
Geir Hiller Holom
  • Geir Hiller Holom
Free Trial
ULTI ULTIMOVACS

Ultimovacs (Sell, TP: NOK2.50) - Slow recruitment continues

We remain concerned about Ultimovacs’s ability to generate significant investor interest ahead of the next financing round, and note that recruitment continues to slow. We have made minor estimate revisions, and see further downside risk on the DOVACC and LUNGVAC trials being fully recruited as guided. We reiterate our SELL and have cut our target price to NOK3 (4).

08/26/24 August 26, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provi...

Ultimovacs ASA Reports Second Quarter 2024 Financial Results and Provides General Business Update Oslo, August 21, 2024: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its second quarter 2024 results today. Conference call and webcast scheduled for August 21, 2024, at 14:00 (CET). Link to webcast . Second Quarter 2024 Business Update Following the negative INITIUM result in March 2024, Ultimovacs implemented cash preservation initiatives during the second quarter of 2024 extending...

August 21, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA: Invitation to second quarter 2024 results webcast pres...

Ultimovacs ASA: Invitation to second quarter 2024 results webcast presentation Oslo, August 15, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, invites to a webcast presentation of its second quarter 2024 results on Wednesday, August 21, 2024. The presentation can be followed as a live webcast accessed through a link on at 14:00 CET on Wednesday, August 21, 2024, and is scheduled to conclude at 14:55 CET. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post...

August 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch